Introduction {#Sec1}
============

Current combination antiretroviral therapy has been successful in suppressing HIV-1 replication to undetectable levels. However, a barrier to the complete eradication of HIV-1 infection by combination antiretroviral therapy is the existence of a small reservoir of latently infected cells \[[@CR1]--[@CR4]\]. A prime candidate for this reservoir is resting CD4^+^ T cells since they are long-lived and can harbor replication-competent proviruses that remain transcriptionally silent in the absence of an activating stimulus \[[@CR5]--[@CR8]\]. Resting CD4^+^ T cells are heterogeneous populations that include naïve (T~N~) and memory (T~M~) cells. T~M~ cells are further divided into central memory (T~CM~), transitional memory (T~TM~), and effector memory (T~EM~) cells. Resting CD4^+^ T~M~ cells have been proposed to be major reservoirs of latent HIV-1 infection, on the evidence of high levels of HIV-1 DNA content \[[@CR5], [@CR9], [@CR10]\]. However, it has also been suggested that resting CD4^+^ T~N~ cells are an important reservoir of latent HIV-1 infection \[[@CR11], [@CR12]\].

A latent reservoir could be established during the early phase of HIV-1 infection \[[@CR1], [@CR6]\], during which CCR5-tropic (R5) HIV-1 is highly transmissible \[[@CR13]--[@CR15]\]. Notably, results from next-generation sequencing suggest that CXCR4-tropic (X4) HIV-1 may be more prevalent during the early phase of HIV-1 infection than previously reported \[[@CR16]\], so that newly infected individuals have usually been exposed to a mixture of X4 and R5 viruses \[[@CR17]--[@CR20]\]. CD4^+^ T cells undergoing effector-to-memory transition are permissive for HIV-1 latent infection \[[@CR21]\]. Latency has also been shown to occur following direct infection of resting CD4^+^ T cells \[[@CR22]\], but it is not yet known which subsets of resting CD4^+^ T cells are involved in the latent infection by X4 and R5 HIV-1.

We previously constructed a recombinant X4 HIV-1 (HIV-1~NL-E~) harboring EGFP reporter gene for expression of a green fluorescent protein, along with an isogenic R5 HIV-1 (HIV-1~NLAD8-D~) harboring DsRed gene, for expression of a red fluorescent protein, enabling us to distinguish between these viruses in productively infected cells \[[@CR23]\]. Here, we investigated the infectivity of these viruses in isolated, primary human resting CD4^+^ T cell subsets (T~N~, CCR5^−^ T~M~, and CCR5^+^ T~M~) in a dual-infection model.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Virus preparation {#Sec4}

To generate HIV-1~NL-E~ and HIV-1~NLAD8-D~ stocks, HEK293T cells were transfected with the corresponding proviral DNA plasmid using the calcium phosphate precipitation method as described previously \[[@CR23]\]. The amount of p24 Gag in the culture supernatant was measured with an in-house enzyme-linked immunosorbent assay \[[@CR24]\]. The supernatant was then filtered, aliquoted, and stored at − 80 °C.

### Cell preparation {#Sec5}

Human peripheral blood was donated by healthy Japanese adult volunteers. Peripheral blood mononuclear cells (PBMCs) were separated by the Lymphocyte Separation Medium 1077 (PromoCell, Heidelberg, Germany). CD4^+^ T cells were first negatively enriched from PBMCs using the EasySep Human CD4^+^ T cell Enrichment Kit (StemCell Technologies, Vancouver, BC, Canada). Enriched CD4^+^ T cells were stained with the following antibodies: CD69-FITC (FN50; ThermoFisher Scientific, Waltham, MA, USA), HLA-DR-Alexa Fluor 488 (L243; BioLegend, San Diego, CA, USA), CD8-PerCP (RPA-T8, BioLegend), CD19-PerCP (HIB19; BioLegend), CD27-Alexa Fluor 700 (O323; BioLegend), CD45RA-PE-Cy7 (HI100; BioLegend), and CCR5-Alexa Fluor 647 (T312; \[[@CR25]\]). Notably, the anti-CCR5 monoclonal antibody T312 does not interfere with the binding of R5 HIV-1 to CCR5 \[[@CR25]\]. Three subsets of resting (CD69^−^HLA-DR^−^) CD4^+^ T cells \[T~N~ (CD45RA^+^CD27^+^CCR5^−^), CCR5^−^ T~M~ (CD45RA^−^CCR5^−^), and CCR5^+^ T~M~ (CD45RA^−^ CCR5^+^)\] were isolated by flow-cytometric sorting using a FACSAria III (BD Biosciences, San Diego, CA, USA). Dead cells stained with the Live/Dead Fixable Violet Dead Cell Stain (ThermoFisher Scientific) were not isolated.

### Infection and culture {#Sec6}

Resting CD4^+^ T-cell subsets isolated by flow cytometry were infected with a 1:1 mixture of X4 and R5 viruses (determined by the amount of p24) at a range of 10--20 ng total p24 per 10^5^ cells by the spinoculation method as previously described \[[@CR26]\]. After spinoculation, cells were washed and then incubated in R-10 medium \[RPMI-1640 with 10% fetal bovine serum, 100 µg/ml penicillin, 100 µg/ml streptomycin, and 1% GlutaMAX solution (ThermoFisher Scientific)\] for 2 h at 37 °C to induce viral fusion. Cells were then washed and cultured in R-10 medium supplemented with 1.25 µM saquinavir, to prevent viral spread, for up to 5 days. At 3 days post-infection, half of the culture medium was replaced with fresh medium, and the cultures were either kept in the resting condition or subjected to activation via the T-cell receptor using the Dynabeads Human T-Activator CD3/CD28 (ThermoFisher Scientific) in the presence of 5% heat-inactivated human AB serum and 50 U/ml IL-2 for 2 days. Flow cytometry was performed to detect productively infected cells at 3 days and 5 days post-infection using a FACSCanto II (BD Biosciences). All experiments with HIV-1 were conducted in a biosafety level 3 containment facility at National Institute of Infectious Diseases (NIID; Tokyo, Japan).

### Analysis for flow cytometry {#Sec7}

Data obtained from flow cytometry were saved as FCS files and analyzed using FlowJo v10.5.0 (BD Biosciences).

### Statistical analysis {#Sec8}

The significance of data comparisons was evaluated by repeated-measures one-way ANOVA and Tukey's multiple comparison test using GraphPad Prism version 8 (Graph Pad Software, San Diego, CA, USA). A *P*-value of \< 0.05 was considered statistically significant.

Results {#Sec9}
-------

### Profiles of resting T~N~-, CCR5^−^ T~M~-, and CCR5^+^ T~M~-cell populations prior to sorting {#Sec10}

For HIV-1 infection and culture experiments, negatively enriched CD4^+^ T cells were prepared from 200 ml each of peripheral blood from three donors. The enriched CD4^+^ T cells were stained with fluorochrome-conjugated antibodies and subjected to flow-cytometric sorting. Resting CD4^+^ T cells were defined as CD69 and HLA-DR double-negative, as described elsewhere \[[@CR27]\], and represented 83.1--94.3% of the enriched CD4^+^ T cells (Fig. [1](#Fig1){ref-type="fig"}a). The resting CD4^+^ T cells consisted of CD45RA^+^CD27^+^CCR5^−^ T~N~, CD45RA^−^CCR5^−^ T~M~, and CD45RA^−^CCR5^+^ T~M~ cells, with CCR5 expressed exclusively on CD45RA^−^ T~M~ cells. The resting CCR5^+^ T~M~ cells were the minor population, with yields of 0.9 × 10^6^ to 2.2 × 10^6^ cells from the three donors. All of the sorted cells were used for HIV-1 infection and culture experiments. In a pilot experiment, the cell-sorting protocol was applied to small-scale samples from two more donors. Resting CCR5^+^ T~M~ cells were isolated at 86.9--93.0% purity, whereas resting T~N~ cells and CCR5^−^ T~M~ cells were isolated at \> 97% purity (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Flow-cytometric cell-sorting isolation strategy for three resting CD4^+^ T-cell subsets. **a** Pre-sorting flow-cytometry profiles of negatively enriched CD4^+^ T cells in PBMCs from three donors. Resting CD4^+^ T cells were negative for expression of CD8, CD19, CD69, and HLA-DR. Memory T cells (T~M~) were CD45RA^−^, whereas naïve T cells (T~N~) were CD45RA^+^CD27^+^. T~M~ cells were either CCR5^+^ or CCR5^−^, whereas T~N~ cells were CCR5^−^. The distribution of CCR5^+^ cells (red) and CCR5^−^ cells (gray) within resting CD4^+^ T cells according to expression of CD45RA and CD27 is shown in the right-hand set of panels. **b** Results of a pilot experiment to test the purity of three resting CD4^+^ T-cell subsets isolated by cell sorting using cell samples from two donors

### Productive HIV-1 infection in resting cells {#Sec11}

The protocol for the study of HIV-1 infection and culture is summarized in Fig. [2](#Fig2){ref-type="fig"}a. The results of flow cytometry showed that X4 HIV-1 productively infected all resting subsets, with EGFP expression in 0.50% ± 0.25% (mean ± SD) of T~N~ cells, 1.83% ± 1.99% of CCR5^−^ T~M~ cells, and 1.76% ± 1.43% of CCR5^+^ T~M~ cells at 3 days post-infection (Fig. [2](#Fig2){ref-type="fig"}b, c and Additional file [1](#MOESM1){ref-type="media"}). The percentage of resting cells with R5 HIV-1 infection was highest in CCR5^+^ T~M~ cells (4.35% ± 0.42%), considerably less in CCR5^−^ T~M~ cells (0.47% ± 0.25%), and very low in T~N~ cells (0.01% ± 0.01%) at 3 days post-infection. In T~N~ cells, extending the culture from 3 to 5 days in the resting condition substantially enhanced both the intensity and frequency of expression of the EGFP reporter, suggesting that productive infection in resting T~N~ cells proceeded more slowly than in resting T~M~ cells.Fig. 2HIV-1 infection and culture of resting CD4^+^ T-cell subsets isolated by cell sorting. Subsets of naïve T cells (T~N~), or CCR5^+^ or CCR5^−^ memory T cells (T~M~), were separately infected and cultured. **a** Schematic of the protocol of HIV-1 infection and culture. **b** Representative flow-cytometry profiles of cells from Donor \#1 at day 3 and day 5 post-infection (resting or activated), separated according to reporter expression indicating the presence of X4 or R5 HIV-1, with the percentage of each subset indicated (left panels). The intensity of fluorescence for each viral reporter in each cell subset \[except for the very low percentage of DsRed^+^ cells (R5^+^) in T~N~ cells\] is shown in the right-hand panels. **c** Percentages of HIV-1^+^ cells in each CD4^+^ T-cell subset in three donors. **d** Percentage increases in frequencies of HIV-1^+^ cells following activation were estimated by comparing percentages of HIV-1^+^ cells in the activation condition with those in the resting condition at day 5 post-infection. Significant differences (\**P* \< 0.05, \*\**P* \< 0.01) were determined by repeated-measures one-way ANOVA followed by Tukey's multiple comparison test. In **c** and **d**, HIV-1^+^ cells include the corresponding reporter (either EGFP or DsRed) single-positive cells and double-positive cells

### Activation increases the frequency of HIV-1 infection in CCR5^+^ T~M~ cells {#Sec12}

Proportions of HIV-1^+^ cells 5 days post-infection were compared in resting cells and cells that were activated on day 3 post-infection, to assess the presence of transcription-silent, replication-competent viral reservoirs (Fig. [2](#Fig2){ref-type="fig"}d). Notably, in the CCR5^+^ T~M~-cell subset, the proportions of both R5 HIV-1^+^ cells and X4 HIV-1^+^ cells were higher in activated cells than in resting cells. In the CCR5^−^ T~M~-cell subset, the frequency of R5 HIV-1^+^ cells was higher following activation, but the difference was not significant. No consistent response to activation in terms of the frequency of X4 HIV-1^+^ cells was observed in either T~N~ or CCR5^−^ T~M~ subset, despite that the robust activation was observed on the basis of the reporter intensity (Fig. [2](#Fig2){ref-type="fig"}b and Additional file [1](#MOESM1){ref-type="media"}).

Discussion {#Sec13}
----------

In this study, we demonstrated by flow cytometry that resting CD4^+^ T cells are subject to productive infection. This result is consistent with findings from other studies, where primary resting CD4^+^ T cells were infected with HIV-1 expressing fluorescent reporter proteins \[[@CR22], [@CR28], [@CR29]\]. The profile of productive infection that we observed was associated with the expression pattern of the coreceptors. In particular, CCR5 is expressed on T~M~ cells, especially the T~EM~ subset, and is rarely detectable on T~N~ cells, whereas CXCR4 is detectable in all CD4^+^ T-cell subsets \[[@CR30], [@CR31]\]. The R5 HIV-1^+^ cells that we detected in the CCR5^−^ T~M~ subset might result from the presence of R5 HIV-1-permissive cells that were not detected for CCR5 expression by flow cytometry, as low levels of CCR5 are sufficient for R5 HIV-1 infection if they are associated with sufficient cell-surface expression of CD4 \[[@CR32]\].

We found that the intensity of the viral reporter fluorescence in resting CD4^+^ T~N~ cells was lower than in resting CD4^+^ T~M~ cells at 3 days post-infection. Previous studies indicated that the low intensity of the viral reporter fluorescence may suggest the presence of unintegrated viral DNA, which is capable of generating infectious virions \[[@CR28], [@CR29]\]. Although we did not determine the levels of integrated proviral DNA and unintegrated viral DNA, our results highlight a replicative advantage of CCR5^+^ memory subsets for both X4 and R5 HIV-1, even in the resting condition.

Our main aim was to determine which subsets of resting CD4^+^ T cells contribute to formation of the latent reservoir in the presence of both X4 and R5 HIV-1. When we compared activated and resting cells at day 5 post-infection, we found consistently higher proportions of R5 HIV-1^+^ cells and X4 HIV-1^+^ cells in the CCR5^+^ T~M~-cell subset following activation. This effect of activation was not seen in T~N~ or CCR5^−^ T~M~ cells. We previously showed that resting CD4^+^ T~N~ cells resist latent HIV-1 reactivation \[[@CR33]\], supporting the present result. Latent HIV-1 reservoirs may exist in T~N~ and CCR5^−^ T~M~ cells, as it is possible that the level of depletion by viral cytopathy just exceeded or was equal to that of generation from latency. However, our results suggest that resting CCR5^+^ T~M~ cells are the major reservoir of replication-competent, latent R5 HIV-1 and X4 HIV-1 among resting CD4^+^ T-cell subsets.

Limitations {#Sec14}
===========

First, we did not investigate whether, after exposure to virus, reporter-negative resting cells possessed proviruses that were induced for viral replication following activation. Second, because we identified preferential infection of R5 HIV-1 over X4 HIV-1 in resting CCR5^+^ T~M~ cells, it was assumed that R5 HIV-1 is more permissive for latent infection in resting CCR5^+^ T~M~ cells than X4 HIV-1. However, it has been reported that X4 laboratory strains such as NL4-3, from which our X4 HIV-1 (HIV-1~NL-E~) was derived, are less effective at infecting cells expressing low levels of CXCR4 than primary isolates \[[@CR34]\]. Indeed, CXCR4 expression levels in CCR5^+^ T~M~ cells are lower than in T~N~ cells (Additional file [2](#MOESM2){ref-type="media"}) \[[@CR31]\]. Our separate experiments demonstrated that the predominance of R5 HIV-1 over X4 HIV-1 had already begun at the binding stage of the infection of CCR5^+^ T~M~ cells (Additional file [3](#MOESM3){ref-type="media"}). Therefore, X4 primary isolates should be tested to evaluate the predominance of latent infection between X4 and R5 viruses.

Additional files
================

 {#Sec15}

**Additional file 1: Fig. S1.** Flow-cytometry profiles of Donor \#2 and Donor \#3 at day 3 and day 5 post-infection. **Additional file 2: Fig. S2.** Comparison of CXCR4 expression between T~N~ and CCR5^+^ T~M~ cells within resting CD4^+^ T cells. **Additional file 3: Fig. S3.** Data from separate experiments for the evaluation of HIV-1 binding (**S3-1**), entry (**S3-2**), and reverse transcription (**S3-3**) in CCR5^+^ T~M~ cells.
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